Physician profile
Samone Desai
NPI 1972076636
$10,212.70
in general payments reported to CMS, 2019-2025
38 companies · $3,191 in 2025
The $3,191 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $489 · 2022: $936 · 2023: $2,108 · 2024: $3,490 · 2025: $3,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,353 · Education: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,352.90 |
| Education | $435.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,526.61 | 2021-2025 | |
| Amgen INC. | $974.62 | 2022-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $937.82 | 2022-2025 | Sotyktu |
| Incyte Corporation | $930.98 | 2021-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $723.28 | 2022-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $646.78 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $590.23 | 2023-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $560.30 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $492.85 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $468.01 | 2021-2025 | Odomzo, Blu-U, Winlevi |
| Novartis Pharmaceuticals Corporation | $359.34 | 2021-2025 | |
| Galderma Laboratories, L.P. | $332.17 | 2024-2025 | Nemluvio, Aklief |
| Mayne Pharma Commercial LLC | $234.31 | 2022-2025 | |
| Ucb, INC. | $206.86 | 2024-2025 | Bimzelx |
| Organon LLC | $150.45 | 2025 | Vtama |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $141.73 | 2023 | Ycanth |
| Regeneron Pharmaceuticals, INC. | $99.99 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $97.68 | 2023-2025 | Cabtreo, Arazlo, Jublia |
| Journey Medical Corporation | $96.40 | 2022-2025 | |
| Genzyme Corporation | $90.79 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $83.91 | 2024-2025 | Zoryve |
| Glaxosmithkline, LLC. | $56.55 | 2021-2022 | |
| Biofrontera INC. | $54.67 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Pfizer INC. | $51.19 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $38.38 | 2021 | |
| Botanix Sb INC | $36.14 | 2025 | Sofdra |
| Kyowa Kirin, INC. | $33.59 | 2022-2024 | Poteligeo |
| Celgene Corporation | $32.32 | 2024 | Sotyktu |
| Kerecis Limited | $23.60 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Almirall LLC | $22.43 | 2025 | Klisyri |
| Sandoz INC. | $18.53 | 2023 | |
| Revance Therapeutics, INC. | $17.07 | 2024 | Daxxify |
| Lnhc, INC | $16.26 | 2025 | Zelsuvmi |
| Esperion Therapeutics, INC. | $15.00 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.12 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.55 | 2021 | |
| Epi Health, LLC | $12.76 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samone Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.